Attached files
file | filename |
---|---|
EX-10.1 - EMPLOYMENT AGREEMENT - AzurRx BioPharma, Inc. | ex10-1.htm |
8-K - CURRENT REPORT - AzurRx BioPharma, Inc. | azrx_8k.htm |
Exhibit
99.1
AzurRx BioPharma Announces Appointment of Daniel Schneiderman as
Chief Financial Officer
NEW
YORK, January 3, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.
(NASDAQ: AZRX) (“AzurRx” or the “Company”),
a company specializing in the development of non-systemic,
recombinant therapies for gastrointestinal diseases, today
announced that Daniel Schneiderman has been appointed to serve as
the Company’s Chief Financial Officer effective January 2,
2020.
Mr.
Schneiderman, who has over 17 years of healthcare and finance
experience, most recently served as Chief Financial Officer for
Biophytis, SA (through its U.S. subsidiary Biophytis, Inc.)
(Euronext Growth Paris: ALBPS) from November 2018 through December
2019. Previously, Mr. Schneiderman served as the Vice President,
Finance, Controller and Corporate Secretary for MetaStat, Inc.
from February 2012 through October 2018. Mr. Schneiderman’s
early career included a number of investment banking positions
where he focused on private and public small capitalization
companies mainly in the healthcare and life sciences sectors. Mr.
Schneiderman was Vice President of Investment Banking for Burnham
Hill Partners LLC, where he worked from 2008 to 2012. From 2004
through 2008, Mr. Schneiderman was Vice President of Investment
Banking at Burnham Hill Partners, a division of Pali Capital,
Inc. Previously, Mr. Schneiderman worked at H.C. Wainwright
& Co., Inc. in 2004 as an investment banking analyst. Mr.
Schneiderman earned a bachelor’s degree in economics from
Tulane University. Mr. Schneiderrman replaces Maged Shenouda, who
left the Company on November 30, 2019 to pursue other career
opportunities.
“We
are very pleased that Daniel Schneiderman is joining AzurRx as
Chief Financial Officer. I am confident that his vast healthcare,
financial, strategic and fundraising experience will allow him to
make a significant contribution to the Company’s future
success,” commented James Sapirstein, President and Chief
Executive Officer.
About
AzurRx BioPharma, Inc.
AzurRx
BioPharma, Inc. (NASDAQ: AZRX) is engaged in the research and
development of non-systemic biologics for the treatment of patients
with gastrointestinal disorders. MS1819-SD recombinant lipase for
EPI is the Company's lead development program, and additional early
stage research is being conducted for the prevention of
hospital-acquired infections. The Company is headquartered in
Brooklyn, NY, with scientific operations based in Langlade,
France. Additional information on the Company can be found
at www.azurrx.com.
Forward-Looking
Statements
This press release may contain certain statements relating to
future results which are forward-looking statements. These
statements are not historical facts, but instead represent only the
Company’s belief regarding future events, many of which, by
their nature, are inherently uncertain and outside of the
Company’s control. It is possible that the Company’s
actual results and financial condition may differ, possibly
materially, from the anticipated results and financial condition
indicated in these forward-looking statements. Additional
information concerning the Company and its business, including a
discussion of factors that could materially affect the
Company’s financial results, including those related to the
clinical development of MS1819-SD and final results of the Phase II
OPTION study, are contained in the Company’s Annual Report on
Form 10-K for the year ended December 31, 2018 under the
heading “Risk Factors,” as well as the
Company’s subsequent filings with the Securities and Exchange
Commission. All forward-looking statements included in this press
release are made only as of the date of this press release, and we
do not undertake any obligation to publicly update or correct any
forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become
aware.
For
more information:
AzurRx BioPharma,
Inc.
760 Parkside Avenue
- Suite 304
Brooklyn, NY
11226
Phone:
(646)-699-7855
info@azurrx.com
Investor
Relations contact:
LifeSci Advisors,
LLC.
Hans Vitzthum,
Managing Director
250 West 55th
Street - Suite 16B
New York, NY
10019
Phone:
617-430-7578
www.lifesciadvisors.com
hans@lifesciadvisors.com